NCT06714383RecruitingPhase 2
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
A Prospective Randomized Phase Ⅱ Study of Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 23 Nov 2024
- Start date
- 13 Nov 2024
- Primary completion date
- Jul 2025
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT06714383
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 13 Nov 2024 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of malignancies of other type;
- Allergic to study agent;
- History of psychotropic substance abuse, alcohol or drug use;
Other
- The researchers considered inappropriate to join the study of any cause.
Who the study is looking for
- Written informed consent signed;
- Classic osteosarcoma confirmed by histopathology (high grade);
- Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria;
- Planned to receive neoadjuvant chemotherapy;
- Measurable disease on CT by RECIST 1.1.
- No antitumor system therapy received;
- ECOG 0-1
- Adequate organ function.
- Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.
Age in the registry: 14 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.